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Introduction: Preliminary clinical evidence suggests a detrimental effect of pathogenic variants of BRCA1
and 2 genes on fertility outcome. This meta-analysis evaluates whether women carrying BRCA mutations
(BRCAm) have decreased ovarian reserve, in terms of Anti-Muellerian Hormone (AMH), compared to
women without BRCAm (wild-type).
Material and methods: Systematic searches of PubMed, Medline, Scopus, Embase, Science Direct and the
Cochrane Library from inception until July 2020 were conducted. All studies comparing AMH level in
fertile age women, with and without BRCA pathogenic variants were considered. Sub-analyses were
performed according to age, presence of breast cancer, and type of mutation.
Results: Among 64 studies, 10 series were included. For the entire cohort, a trend of reduced AMH level
were found between BRCAm carriers and women without pathogenic variants. BRCAm carriers aged 41-
years or younger had lower AMH levels compared to 41-years or younger wild type women (OR: 0.73
[95%CI-1.12;-0.35]; p ¼ 0.0002). This finding was confirmed for BRCA1m carriers (OR: 1 [95%CI-1.96;-
0.05]; p ¼ 0.004) whereas no difference was observed between BRCA2m carriers and wild type
women. The same analysis on breast cancer patients with and without BRCAm achieved the same results.
Conclusion: Young BRCA1m carriers seem to have lower AMH level compared with wild type women and
therefore a potential decreased ovarian reserve.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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T he lifetime risk of ovarian and breast cancer (BC) in women
with pathogenic variants in BRCA1 and BRCA2 gene is 72% and 69%,
44% and 17%, respectively [1]. NCCN guidelines recommend a risk-
reducing removal of ovaries and fallopian tubes between ages 35
and 40 and upon completion of child bearing for BRCA1 mutation
(BRCA1m) carriers. Delaying risk-reducing removal of ovaries and
fallopian tubes until age 40e45 is reasonable for women carrying
BRCA2 mutation (BRCA2m) because the average age of ovarian
cancer onset is 8e10 years later than in BRCA1m [2]. The implica-
tions of BRCA pathogenic variants on women's reproductive health
are still uncertain. Therefore, no clear data can be specifically pro-
vided to patients facing this fight against biological timing.
BRCA1 and BRCA2 genes play a key role in DNA double-strand
breaks (DBSs), chromosomal stability, apoptosis and cell cycle [3].
Therefore, a deficiency in these genes may result in meiotic errors
and predispose to apoptosis [4]. In vitro experiments showed that
BRCA pathogenic variants could lead to oocyte apoptosis and pre-
mature follicular depletion [5]. BRCA 1-mutant mice showed lower
number of primordial follicle and a reduced response to ovarian
stimulation [6]. In breast cancer patients undergoing ovarian
stimulation for fertility preservation, patients carrying BRCA
pathogenic variants achieved poorer response to ovarian stimula-
tion compared to non-mutated breast cancer patients [7,8]. Some
authors reported comparable ovarian reserve and responses to
ovarian stimulation in BRCAm carriers with and without breast
cancer, compared with women with BRCA negative cancer and
cancer free controls [9,10]. On the contrary, recent studies on
BRCAm carriers have shown less ovarian reserve and a higher rate
of earlier onset of menopause on average than women without the
pathogenic variant [11,12].
Anti-Mullerian Hormone (AMH) is a biomarker of ovarian
reserve. It reflects ovarian aging and is one of the most relevant
indicators of women's fertility potential [13]. AMH plays a role in
the primary follicle depletion rate and its values appear to corre-
spond well with antral follicle counts and fertility potential [14,15].
It also correlates with the number of oocytes retrieved following
ovarian stimulation for fertility treatment [16]. AMH decreases
with age and predicts age of menopause [17,18].
The predictive value of the ovarian reserve and whether lower
AMH in BRCAm carriers places breast cancer patients at a higher
risk for chemotherapy-induced ovarian failure were recently
investigated. Presence of a deleterious BRCA germline mutation did
not affect AMH level in breast cancer patients undergoing chemo-
therapy and endocrine therapy [19].
The aim of the meta-analysis was to compare AMH levels as a
marker of ovarian reserve between BRCAm carriers and women
without mutations (wild type).1562. Material and methods
2.1. Data identification and selection
This systematic review and meta-analysis was performed ac-
cording to the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) statement. On July 2020, the sys-
tematic literature search was performed. All eligible studies were
included without restriction on publication year and/or language.
The studies were identified using the electronic databases PubMed,
Medline, Scopus, Embase, Science Direct, and the Cochrane Library
adopting the search terms “AMH” or “anti-mullerian hormone” and
“BRCA” “BRCA1” “BRCA2” and “ovarian reserve”. All original articles
comparing the AMH level of BRCAm carriers and wild type were
included. The study groups were the following: BRCAm breast
cancer women and not affected BRCAm carriers. The control groups
consisted of breast cancer and cancer-free women tested for BRCA
and resulted negative. All women were in fertile age, assessed by
regular menses. Only women tested for BRCA have been considered
for the analysis. In all eligible studies, as well as in our analysis, the
outcome was AMH as the marker of ovarian reserve. Reference lists
of already published reviews and original reports were also
analyzed in order to identify potential studies. Review articles, case
reports, studies on animal models and protocols, were excluded.
For studies not reporting relevant data, such as standard deviation
and/or mean, the first/last/corresponding authors of these studies
were questioned in order to provide additional information. The
authors who confidentially provided these data were acknowl-
edged in the specific section and their studies were included in the
analysis. The studies from authors unable to provide this missing
information were excluded from the analysis.
2.2. Data extraction and outcomes
For each study included in the meta-analysis, the following data
were recorded: first author's information and publication year, type
of patients (breast cancer patients undergoing fertility
preservation/cancer-free women tested for BRCA undergoing sur-
veillance program), number of BRCAm women/total, study groups
available for comparison, type of the study, age of patients (range),
major matching criteria/adjusted variables. The primary outcome
was the ovarian reserve, defined by the level of AMH in ng/mL. It
was reported in meanþ/-standard deviation for each study and
control group. Sub-analyses have been performed based on age and
presence of breast cancer.
When the series reported the AMH level of women carrying
BRCA1 and 2 pathogenic variants as a unique mean value, no sub-
analyses for BRCA1m and BRCA2m were performed. When
BRCA1m and 2 data were also presented separately, a sub-analysis
on BRCA1m and BRCA2m was performed. When studies reported
data only on BRCA1m or BRCA2m, these data were considered only
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2 m forest plot.
The following comparisons were considered: 1. BRCAm 1 and 2
carriers with or without breast cancer (study group) versus wild
type women with or without breast cancer (control group); 2.
BRCAm carriers with or without breast cancer under 42 years old
(study group) versus not mutation carriers (wild type) with or
without breast cancer under 42 years old (control group); 3.
BRCA1m carriers with and without breast cancer (study group)
versus wild type women with and without cancer (control group);
4. BRCA1m carriers with and without breast cancer under 42 years
old (study group) versus wild typewomenwith and without cancer
under 42 years old (control group); 5. BRCA2m carriers with and
without breast cancer (study group) versus wild type women with
and without cancer (control group); 6. BRCA2m carriers with and
without breast cancer under 42 years old (study group) versus wild
type women with and without cancer under 42 years old (control
group); 7. BRCA1m breast cancer patients undergoing fertility
preservation under 42 years old (study group) versus wild type
breast cancer patients undergoing fertility preservation under 42
years old (control group); 8. BRCA2m breast cancer patients un-
dergoing fertility preservation under 42 years old (study group)
versus wild type breast cancer patients undergoing fertility pres-
ervation under 42 years old (control group).
2.3. Statistical analysis
A c2 test for heterogeneity among proportions was performed
to verify the presence of statistical heterogeneity between studies.
The pooled odds ratio (OR) was calculated using a fixed- or
random-effects model, according to the most suitable model to the
sampling frame, and not on the basis of the heterogeneity. Under
the fixed-effects model, we assumed one true effect size that
underpinned all the studies included in that analysis, and that all
differences in observed effects were due to sampling error. Under
the random-effects model we allowed that the true effect size
might differ from study to study and a more intensive variant of
intervention was used. Briefly, under fixed-effects model it was
reasonable to assume that studies were similar enough and that
there was a common effect. Furthermore, the fixed-effects model
was used only when the number of studies included in the analysis
was less than five. Graphical representation of each study and
pooled analysis was displayed by forest plots. The weight that each
study provides in the meta-analysis was graphically reported as a
square of different size. Confidence intervals (CIs) for each study
were symbolized as a horizontal line passing through the square.
The pooled OR was represented as a lozenge in the forest plot and
its size corresponded to the 95% CI of the OR. A p value  0.05 was
considered significant. The data extracted from the studies
included in the meta-analysis were analyzed using Review Man-
ager (RevMan), Version 5.3, Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014.
3. Results
Overall, 64 studies were identified through the literature search.
Of these, 27 studies were removed as duplicates and 37 were
screened. Of these, 30 were excluded after title and abstract eval-
uation because 9 were reviews, 2 were case reports, 1 was a pro-
tocol proposal, 6 studies had different aims, 3 studies were in vitro
molecular analyses or carried out on animals, two articles were case
reports, 1 study did not report the AMH levels and in another three157papers the AMH levels were only reported as median (instead of
mean) or with mean without standard deviation [20e22], and 1
article focused on endometriosis. One study apparently fulfilling
inclusion criteria, categorized women as low risk due to a negative
family history for breast and/or ovarian cancer, without a confir-
mation BRCA test, therefore it was excluded [23]. At the end of the
screening, ten studies resulted eligible and were included in the
meta-analysis [5,6,10,24e30]. The group populations of the ten
selected studies, considered as upper limit 40 [24e26], 42 [6], and
45 years old [5,27e30]. Age related sub-analyses were performed
from the higher age (45 years) to the lower until a statistical sig-
nificancewas detected. A statistical significancewas detected at the
cut-off of 42 years of age.
Fig. 1 represents the PRISMA flow diagram of the identification,
screening, eligibility, and inclusion process described above. Over-
all, 1644 women tested for BRCAmwere included in the analysis. Of
those tested for BRCA, 830/1644 (50.5%) were BRCA/12m carriers.
The characteristics of these ten studies are reported in Table 1.
Based on the Cochrane risk-of-bias assessment, some studies
exhibited significant bias mostly in terms of the personnel blinding
process because of the nature of the interventions (Table 2).
3.1. AMH in BRCA1/2m carriers with and without breast cancer
versus wild type women
When comparing AMH of women carrying BRCA1-2 pathogenic
variants with and without breast cancer to wild type women with
and without breast cancer, five studies were included
[5,6,10,24,26]. The analysis revealed that BRCAm carriers have
similar AMH levels to wild-type women (OR: 0.48 [95%CI -1.03;
0.08]; p¼ 0.09), despite a trend of reduced AMH levels inwild-type
women (Fig. 2). However, at an exploratory analysis including only
women aged under 42 years, AMH level is statistically lower in
BRCAm women (OR: 0.73 [95%CI -1.12; 0.35]; p ¼ 0.0002)
(Fig. 3).
3.1.1. ✓ BRCA1m
When comparing AMH of BRCA1m breast cancer patients to
wild type breast cancer patients, nine studies were included
[5,6,10,25e30]. The analysis revealed that BRCA1m carriers have
similar AMH levels to wild type women (OR: 0.34 [95%CI -0.79;
0.11]; p ¼ 0.14) (Fig. 4). However, when women under 42 years are
selected, AMH level is statistically lower in BRCA1m women
(OR: 1 [95%CI -0.05; 0.35]; p ¼ 0.04) (Fig. 5).
3.1.2. ✓ BRCA2m
When comparing AMH of BRCA2m breast cancer patients to
wild-type breast cancer patients, seven studies were included
[5,6,10,26,27,29,30]. The analysis revealed that BRCA2m carriers
have similar AMH levels compared to wild type women (OR: 0.01
[95%CI -0.35; 0.36]; p ¼ 0.97) (Fig. 6). No differences were found
when a sub-analysis of only women under 42 years was performed
(OR: 0.26 [95%CI -1.47; 0.96]; p ¼ 0.68) (Fig. 7).
3.2. AMH in breast cancer patients undergoing fertility preservation
in under 42y
When comparing AMH of BRCA1m and BRCA2m breast cancer
patients under age 42 to wild type breast cancer patients, two
studies were included [6,25]. The AMH level of BRCA1m patients
was statistically lower compared towild type breast cancer patients
(OR: 1.18 [95%CI -1.71; 0.66]; p < 0.0001) (Fig. 8. No differences
Fig. 1. PRISMA flow diagram on the Meta-analysis process.
Table 1
Characteristics of the included studies.
Authors, year Setting Program BRCAm/
Tot*
Study groups available for comparison Design of the
study
Age Restriction or matching
for major confounding
factors/adjusted variables




BRCAm 1 þ 2
60 WT




Age, BMI, smoke, HC
27 BRCA2m
BRCAm 1 þ 2
54 WT
Phillips KA, 2016 Cancer-free S 319/535 216 WT Prospective 25
e45
Age, BMI, smoke, HC
172 BRCA1m
147 BRCA2m
Giordano S, 2016 Cancer-free S 68/124 68 BRCA1m Retrospective 18
e45
Age, BMI, HC, smoke, PCOS
56 WT
Johnson L, 2017 Cancer-free S 105/131 55 BRCA1 Prospective 18
e45














Gunnala V, 2019 Cancer- free and
BC"





31 BRCAm 1 (BC þ cancer-free) 18 BRCAm 2
(BC þ cancer-free)
Grynberg, 2019 BC ART (FP) 52/329 52 BRCAm 1 þ 2 Retrospective 18e40 Age, BMI
277 WT
Ponce 2020 Cancer- free S 69/135 32 BRCA1 Retrospective 18e45 Age, PCOS, smoke, BMI,
HC37 BRCA2
66 WT
BC: breast cancer; S: surveillance; ART: assisted reproductive technology; FP: fertility preservation; WT: wild type; HC: hormonal contraceptive use.
*tot. ¼ BRCAm þ wild type (confirmed by BRCA test).
# The cancer-free BRCAm carriers (n ¼ 19) were not considered for the comparison with the cancer-free group without mutation (cancer-free control group).
(n ¼ 600), since the cancer-free control group was not tested for BRCA and was defined only as low risk.
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cancer patients were found (OR:0.68 [95%CI -1.52; 0.15]; p¼ 0.11)
(Fig. 9).1584. Discussion
The results of this meta-analysis carried out on 1644 women
overall showed a non-significant trend of reduction in AMH levels
Table 2
Bias assessment.
Type of Bias Selection Bias Performance Bias Detection Bias Attrition Bias
Study
Titus S, 2013 low low low low
Wang ET, 2014 intermediate low intermediate intermediate
Phillips KA, 2016 intermediate low low low
Giordano S, 2016 high low intermediate low
Johnson L, 2017 high low low low
Ben-Aharon I, 2018 intermediate low low low
Porcu E, 2019 low low low low
Gunnala V, 2019 intermediate low intermediate high
Grynberg, 2019 intermediate low intermediate low
Ponce 2020 high low intermediate low
Fig. 2. AMH in BRCAm 1/2 breast cancer and cancer-free women versus wild-type non cancer women.
Fig. 3. AMH in BRCAm 1/2 breast cancer and cancer-free women versus wild-type non cancer women in under 42y
Fig. 4. AMH in BRCA1m breast cancer and cancer-free women versus wild-type non cancer women.
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atory analysis including only patients of younger age demonstrated
a decrease in AMH levels among BRCAm. In particular, when
BRCAm 1 and 2 carriers were analyzed separately, only women
under 42 carrying a BRCA1 pathogenic variant showed a signifi-
cantly lower AMH level compared towild typewomen. This finding
was also apparent when breast cancer patients with and without
BRCA pathogenic variants undergoing fertility preservation were159analyzed separately to breast cancer-free women. When the com-
parisons included also older women, the significance was missed.
These data may be interpreted by the AMH decrease with
increasing aging, making it difficult to get a significant p-value in
older women.
Youngwomen carrying the BRCA1 or BRCA2 pathogenic variants
have challenging decisions regarding their reproductive life and
childbearing future and require careful counseling on this topic
Fig. 5. AMH in BRCA1m breast cancer and cancer-free women versus wild-type non cancer women in under 42y
Fig. 6. AMH in BRCA2m breast cancer and cancer-free women versus wild-type non cancer women.
Fig. 7. AMH in BRCA2m breast cancer and cancer-free women versus wild-type non cancer women in under 42.
Fig. 8. AMH in breast cancer patients undergoing fertility preservation in under 42y: BRCA1m versus wild-type.
Fig. 9. AMH in breast cancer patients undergoing fertility preservation in under 42y: BRCA2m versus wild-type.
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recommend risk-reducing bilateral salpingo-oophorectomy be-
tween ages 35 and 40 and upon completion of childbearing [2]. The
early onset of menopause in these patients is currently a topic of
interest and strategies to reduce the symptoms are currently160promoted [33]. However, many women are nulliparous when they
receive this diagnosis and there is no specific recommendation for
routine evaluation of fertility potential and ovarian reserve in fe-
male BRCAm carriers. Currently, indications to ART for BRCAm
carriers, are the same as for wild type women.
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integrity of the genome through the repair of homologous recom-
bination (HR). On one side, the deficient HR repair causes prema-
ture depletion of the primordial ovarian pool [6]. Results from
transgenic mice on the impairment of heterologous recombination
repair were confirmed in BRCA1m carriers with accelerated loss of
ovarian follicular reserve and accumulation of DNA double-strand
breaks in oocytes. On the other side, BRCA genes maintain the
chromosome telomere integrity and telomeres, which shorten after
each cycle of DNA replication, being associated with ovarian aging
and reproductive senescence [34e36]. Considering that factors
affecting cell cycle division and DNA repair may also affect repro-
ductive life span, it might be reasonable that defects in BRCA genes
may affect reproduction.
Although BRCAm carriers are more likely to have a poor
response to ovarian stimulation [7], Grynberg at al. have recently
shown that BRCA1/2 pathogenic variants do not seem to affect the
capacity of oocytes to mature in vitro in breast cancer patients
candidate for fertility preservation [26]. When assessing the
ovarian reserve in vivo, the marker that best reflects the gradual
decline in reproductive capacity with increasing age is the AMH
[37].
In our meta-analysis, the presence of the BRCA1 pathogenic
variant did not affect AMH level significantly in the analysis
without age restriction, but the trend towards lower AMH level was
close to statistical significance. The significance was achieved for
BRCA1mwhen only women under 42 years were considered. AMH
level in BRCA2mwas not influenced by age, also when the age was
lowered at 42 and 40 years old (data not shown).
Wang et al. suggest that the difference between BRCA1m and
BRCA2m carriers may be attributable to a differential effect on
ovarian reserve as the epidemiology of ovarian cancer differs be-
tween the two pathogenic variants as well [5]. Firstly, BRCA1
pathogenic variants carry a higher lifetime risk of ovarian cancer
occurring over a decade earlier than BRCA2-associated ovarian
cancers [1,38]. This difference in age penetrance is mirrored by
in vitro studies of age-related decline in BRCA1 gene expression in
human oocytes from reproductive-age women [6]; however, this
was not noted for BRCA2 gene expression, speculating that the
decline may occur in later years. Secondly, BRCA1 and BRCA2 have
distinct molecular functions in the DNA repair pathway and BRCA2
plays a more limited role in homologous recombination repair, thus
anticipating its minor impact on oocyte depletion. There are limited
data regarding oocyte quality of BRCAm carriers, and future in-
vestigations may be focused on this topic.
We acknowledge some inherent limits to this study. As is typical
for meta-analyses, biases may derive from the inclusion criteria of
each study. When comparing women with and without BRCA
pathogenic variants undergoing fertility preservation, all women
with a history of non-breast cancer and/or ovarian surgery, gona-
dotoxic therapy before presentation, ovarian dysfunction (e.g.
PCOS), were excluded in order to avoid interference with AMH
level. However, interference with AMH level may persist in some
cases. Further limit may be related to the different methodology
adopted in the studies for the AMH testing. Until recently, AMH has
been measured with an enzyme-linked immunosorbent assay
(ELISA), which is a manual technique characterized by large
analytical variation; however, automated assays have recently been
introduced for measuring AMH.
Giordano et al. evaluated only BRCA1m carriers and found
reduced AMH levels in >35 year-old women only [28], however in
order to avoid bias when comparing these data with the other se-
ries, we included the mean value of the entire cohort that was
confidentially provided from the authors we contacted. Other au-
thors considered patients from 18 or 25y to 40 or 45y together,161however, all the studies were matched/adjusted for age. Other
confounders were also considered in the studies (e.g. BMI, PCOS,
smoke, use of hormonal therapy), however it is reasonable to as-
sume that internal biases in the study and control group may
persist. As for instance, Gunnala et al. found a large difference in
mean age between the BRCA carriers and BRCA non carriers,
despite the groups being adjusted for age [10].
Furthermore, case and control women underwent BRCA testing
because of personal or familiar history of cancer and results were
negative, according to genetic counseling. However, we cannot
exclude that other kinds of unexplored genetic alterations may
interfere with the reduction in ovarian reserve to a greater extent
than BRCA genes. In BRCAm breast cancer patients, determining the
difference with wild type women in terms of age at menopause,
and pregnancy rate might be biased by the gonadotoxicity of cancer
treatments, similarly the risk reducing strategies might affect the
cancer free BRCAm women. Therefore, these data are still missing
and not in the scope of our study.
5. Conclusion
Young BRCA1m carriers seem to have lower AMH levels
compared with wild type women.
It is unclear whether the lower AMH levels we observed
translate into a reduced ovarian reserve and pregnancy rate.
Additionally, if the awareness of the BRCA pathogenic variants
unconsciously leads to an anticipated median age of conception is
still to be investigated. Given the impossibility to design random-
ized clinical trials with this aim, this type of study represents the
best available evidence that can be achieved. If further studies will
confirm this hypothesis, once the pathogenic variant is diagnosed,
physicians might consider to initiate an infertility work-up and
address these women to a fertility preservation program with a
faster pace. Additionally, If the decreased ovarian reserve in
BRCAm1 will be confirmed in future trials, the possible increased
risk of gonadotoxicity in breast cancer patients carrying the BRCA1
pathogenic variant should be another issue to consider when
counseling these patients.
Declaration of competing interest
The authors have nothing to declare. They have no conflict of
interest.
Acknowledgement
Wewould like to sincerely thank Dr. Mary Ellen Pavone from the
Department of Obstetrics and Gynecology of the Northwestern
University Feinberg School of Medicine in Chicago, Illinois, and Dr.
Kelly-Anne Phillips, from the Division of Cancer Medicine of the
University of Melbourne, Parkville, Australia, for providing us the
additional data of their series. These data were helpful in per-
forming our analysis with a reduced risk of bias.
References
[1] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and
contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med
Assoc 2017;317(23):2402e16.
[2] National Comprehensive Cancer Network: NCCN clinical practice guidelines in
oncology. Genetic/familial high risk assessment: breast and ovarian version
1.2020.
[3] White RR, Vijg J. Do DNA double-strand breaks drive aging? Mol Cell
2016;63(5):729e38.
[4] Ali Jazayeri, Falck Jacob, Lukas Claudia, et al. ATM- and cell cycle-dependent
regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol
2006;8(1):37e45.
M.L. Gasparri, R. Di Micco, V. Zuber et al. The Breast 60 (2021) 155e162[5] Wang Erica T, Pisarska Margareta D, Bresee Catherine, et al. BRCA1 germline
mutations may Be associated with reduced ovarian reserve. Fertil Steril
2014;102(6):1723e8.
[6] Titus Shiny, Li Fang, Stobezki Robert, Akula Komala, et al. Impairment of
BRCA1-related DNA double-strand break repair leads to ovarian aging in mice
and humans. Sci Transl Med 2013;5(172).
[7] Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with
occult primary ovarian insufficiency: a possible explanation for the link be-
tween infertility and breast/ovarian cancer risks. J Clin Oncol 2010;28(2):
240e4.
[8] Turan V, Bedoschi G, Emirdar V, et al. Ovarian stimulation in patients with
cancer: impact of letrozole and BRCA mutations on fertility preservation cycle
outcomes Reprod. Science 2018;25(1):26e32.
[9] Moran Shapira, Raanani Hila, Feldman Baruch, et al. BRCA mutation carriers
show normal ovarian response in in vitro fertilization cycles. Fertil Steril
2015;104(5):1162e7.
[10] Gunnala Vinay, Fields Jessica, Irani Mohamad, et al. BRCA carriers have similar
reproductive potential at baseline to noncarriers: comparisons in cancer and
cancer-free cohorts undergoing fertility preservation. Fertil Steril
2019;111(2):363e71.
[11] Rzepka-Gorska Izabella, Tarnowski Bogusław, Chudecka-Głaz Anita, et al.
Premature menopause in patients with BRCA1 gene mutation. Breast Canc Res
Treat 2006;100(1):59e63.
[12] Finch Amy, Valentini Adriana, Greenblatt Ellen, et al. Frequency of premature
menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril
2013;99(6):1724e8.
[13] Broer Simone L, Broekmans Frank JM, Laven Joop SE, et al. Anti-Müllerian
hormone: ovarian reserve testing and its potential clinical implications. Hum
Reprod Update 2014;20(5):688e701.
[14] de Vet Annemarie, Laven Joop SE, Frank H de Jong, et al. Antimüllerian hor-
mone serum levels: a putative marker for ovarian aging. Fertil Steril
2002;77(2):357e62.
[15] J van Rooij 1 IA, Broekmans FJM, te Velde ER, et al. Serum anti-müllerian
hormone levels: a novel measure of ovarian reserve. Hum Reprod
2002;17(12):3065e71.
[16] Patrelli TS, Gizzo S, Sianesi N, et al. Antimullerian hormone serum values and
ovarian reserve: can it predict a decrease in fertility after ovarian stimulation
by ART cycles? PloS One 2012;7(9):e44571.
[17] van Disseldorp J, Faddy MJ, Themmen APN, et al. Relationship of serum
antimüllerian hormone concentration to age at menopause. J Clin Endocrinol
Metab 2008;93(6):2129e34.
[18] Kwee Janet, Schats Roel, McDonnell Joseph, et al. Evaluation of anti-müllerian
hormone as a test for the prediction of ovarian reserve. Fertil Steril
2008;90(3):737e43.
[19] Lambertini Matteo, Olympios Nathalie, Lequesne Justine, et al. Impact of
taxanes, endocrine therapy, and deleterious germline BRCA mutations on
anti-müllerian hormone levels in early breast cancer patients treated with
anthracycline- and cyclophosphamide-based chemotherapy. Front Oncol
2019;9:575.
[20] Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and per-
formance of fertility preservation strategies in BRCA-mutated breast cancer
patients. Ann Oncol 2018;29(1):237e43.
[21] Son KA, Lee DY, Choi DS. Association of BRCA mutations and anti-muellerian
hormone level in breast cancer patients. Front Endocrinol 2019;10:235.162[22] Van Tilborg TC, Derks-smeets IAP, Boss AME, et al. Serum AMH levels in
healthy women from BRCA 1/2 mutated families: are they reduced? Hum
Reprod 2016;31(11):2651e9.
[23] Michaelson-Cohen R, Mor P, Srebnik N, et al. BRCA mutation carriers do not
have compromised ovarian reserve. Int J Gynecol Canc 2014;24(2):233e7.
[24] Ben-Aharon I, Levi M, Margel D, et al. Premature ovarian aging in BRCA car-
riers: a prototype of systemic precocious aging? Oncotarget 2018 Mar
23;9(22):15931e41.
[25] Porcu Eleonora, Maria Cillo Giulia, Cipriani Linda, et al. Impact of BRCA1 and
BRCA2 mutations on ovarian reserve and fertility preservation outcomes in
Young women with breast cancer. J Assist Reprod Genet 2019 [epub ahead of
print].
[26] Grynberg M, Dagher Hayeck B, Papanikolaou EG, et al. BRCA1/2 gene muta-
tions do not affect the capacity of oocytes from breast cancer candidates for
fertility preservation to mature in vitro. Hum Reprod 2019;34(2):374e9.
[27] Ponce Jordi, Fernandez-Gonzalez Sergi, Calvo Iris, et al. Assessment of ovarian
reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers. Int J
Gynecol Canc 2020;30(1):83e8.
[28] Giordano S, Garrett-Mayer E, Mittal N, et al. Association of BRCA1 mutations
with impaired ovarian reserve: connection between infertility and breast/
ovarian cancer risk. J Adolesc Young Adult Oncol 2016;5(4):337e43.
[29] Johnson Lauren, Sammel Mary D, Domchek Susan, et al. Antimüllerian hor-
mone levels are lower in BRCA2 mutation carriers. Fertil Steril 2017;107(5):
1256e65. e6.
[30] Phillips KA, Collins IM, Milne RL, et al. Anti-Müllerian hormone serum con-
centrations of women with germline BRCA1 or BRCA2 mutations. Hum
Reprod 2016;31(5):1126e32.
[31] Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and
post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical
Practice Guidelines. Ann Oncol 2020;31(12):1664e78.
[32] Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA
mutation carriers and other breast/ovarian hereditary cancer syndromes:
ESMO Clinical Practice Guidelines for cancer prevention and screening. Oncol
2016;27(suppl 5):v103e10.
[33] Gasparri Maria Luisa, Taghavi Katayoun, Fiacco Enrico, et al. Risk-reducing
bilateral salpingo-oophorectomy for BRCA mutation carriers and hormonal
replacement therapy: if it should rain, better a drizzle than a storm. Medicina
(Kaunas) 2019;55(8).
[34] Keefe David L, Marquard Kerri, Liu Lin. The telomere theory of reproductive
senescence in women. Curr Opin Obstet Gynecol 2006;18(3):280e5.
[35] Pan Hua, Ma Pengpeng, Zhu Wenting, et al. Age-associated increase in
aneuploidy and changes in gene expression in mouse eggs. Dev Biol
2008;316(2):397e407.
[36] Terry Hassold, Hunt Patricia. Maternal age and chromosomally abnormal
pregnancies: what we know and what we wish we knew. Curr Opin Pediatr
2009;21(6):703e8.
[37] Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone
values for 17,120 women presenting to fertility centers within the United
States. Fertil Steril 2011;95(2):747e50.
[38] Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian
cancer associated with BRCA1 or BRCA2 mutations detected in case series
unselected for family history: a combined analysis of 22 studies. Am J Hum
Genet 2003;72(5):1117e30.
